Percepta™ CRT-Ps are enabled with BlueSync™ technology, allowing for tablet-based programming and app-based remote monitoring. These devices include exclusive algorithms to optimize CRT and manage atrial fibrillation (AF).Download Brochure
Quad CRT-P MRI SureScan™
Percepta™ Quad CRT-P MRI SureScan™ estimated longevity is greater than that of Viva™ CRT-P.†
Improvement in CRT patient response with AdaptivCRT™||5
Reduction in a patient’s odds of 30-day HF readmission with AdaptivCRT6
AdaptivCRT is associated with a 29% relative reduction in mortality¶7
46% reduction in AF risk with AdaptivCRT Algorithm#8
Incidence of Primary End Point
(≥ 48 consecutive hours of AT/AF)
36% relative reduction in AT/AF episodes ≥ 7 days with Reactive ATP™ Algorithm**9
Incidence of AT/AF Events Lasting 7 or More Days
BlueSync technology within Percepta enables secure, wireless communication.
Percepta CRT-Ps and
Percepta Quad CRT-Ps
Time to a clinical decision was ~7x faster with the use of Medtronic CareAlert notifications compared to standard office follow-up.10
Enhanced with additional features, including BlueSync™ technology and MRI SureScan™ technology, when compared to Viva CRT-P.
Estimated with AdaptivCRT programmed to BIV and LV.
Viva CRT-P projected service life estimates assume device configuration at 50% AP, 50% RVP, 100% LVP, 2.5 V in both A and RV, 3.0 V in LV, 500 Ω lead impedances for all three chambers, and pre-storage EGM OFF. Projected service life estimates are based on accelerated battery discharge data and device modeling. The values calculated based on this information should not be interpreted as precise numbers. Individual patient results may vary based on their specific programming and experience.
Percepta CRT-P projected service life estimates assume device configuration at 50% AP, 50% RVP, 100% LVP, 2.5 V in A, RV, and LV, 500 Ω lead impedances for all three chambers, and prearrhythmia EGM storage programmed to On for the device lifetime. Projected service life estimates are based on accelerated battery discharge data and device modeling. The values calculated based on this information should not be interpreted as precise numbers. Individual patient results may vary based on their specific programming and experience.
Comparing AdaptivCRT to Echo-optimized BiV pacing in patients with normal AV conduction, percentage of patients improved in Packer clinical composite score (CCS) at 6-month follow-up. CCS is a composite measure of mortality, HF hospitalizations, and symptomatic changes.
Patients who received AdaptivCRT were associated with a 29% relative reduction in all-cause mortality vs. conventional CRT (after adjusting for other potential risk factors including age, gender, LVEF, NYHA class, QRS duration, AF, CAD, hypertension, AV block, and LBBB).
Most of the reduction in AF occurred in subgroups with prolonged AV conduction at baseline and with significant left atrial reverse remodeling.
Compared to matched control group.
Medtronic Viva™ CRT-P Model C6TR01 device manual.
Medtronic Percepta™ CRT-P MRI SureScan™ W1TR01 device manual. M985587A001 REV. A.
Medtronic Percepta™ Quad CRT-P MRI SureScan™ Model W4TR01 device manual.
Lulic T. March 26, 2013. Medtronic data on file.
Birnie D, Lemke B, Aonuma K, et al. Clinical outcomes with synchronized left ventricular pacing: analysis of the adaptive CRT trial. Heart Rhythm. September 2013;10(9):1368-1374.
Starling RC, Krum H, Bril S, et al. Impact of a Novel Adaptive Optimization Algorithm on 30-Day Readmissions: Evidence From the Adaptive CRT Trial. JACC Heart Fail. July 2015;3(7):565-572.
Singh JP, et al. Improved Survival With Dynamic Optimization Of CRT Pacing Using AdaptivCRT Algorithm: Analysis Of Real-world Patient Data. Presented at HRS 2018 (Abstract B-AB37-06); Boston, MA.
Birnie D, Hudnall H, Lemke B, et al. Continuous optimization of cardiac resynchronization therapy reduces atrial fibrillation in heart failure patients: Results of the Adaptive Cardiac Resynchronization Therapy Trial. Heart Rhythm. December 2017;14(12):1820-1825.
Crossley GH, Padeletti L, Zweibel S, Hudnall JH, Zhang Y, Boriani G. Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias. Pacing Clin Electrophysiol. July 2019;42(7):970-979.
Crossley GH, Boyle A, Vitense H, Chang Y, Mead R, CONNECT Investigators. The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) Trial: The Value of Wireless Remote Monitoring With Automatic Clinician Alerts. J Am Coll Cardiol. March 2011;57(10):1181-1189.
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.